NovoSeven® RT responds with speed to control their bleeds1-3,a
Want to watch a movie
at my house tonight?
OK. Sounds fun!
My mom says she’ll
order pizza, too.
Sweet! See you in
a few hours.
BRAXTON
Braxton has congenital hemophilia with inhibitors
pd-aPCC=plasma-derived activated prothrombin complex concentrate.
In patients with hemophilia A or B with inhibitors.
Individual doses are compared and based on a 22-kg patient receiving a single dose (90 mcg/kg of NovoSeven® RT or 75 U/kg of pd-aPCC) for a joint bleed.
c
Patients are cautioned that the maximum injection or infusion rate of pd-aPCC must not exceed 2 units per kg of body weight per minute.
d
Median of 2 doses.
Print-only content
e
Data from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with and without an inhibitor. Patients were given NovoSeven®
at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent”
if patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less.
An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated
detectable relief of pain/tenderness or decrease in bleeding.3
a
b
Indications and Usage
NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:
• Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with
inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet
transfusions, with or without antibodies to platelets
• Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia
Important Safety Information
WARNING: THROMBOSIS
• Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
• Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will
receive NovoSeven® RT.
• Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.
Warnings and Precautions
• Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.
Please see additional Important Safety Information on facing page.